


EATRIS is the European infrastructure for translational medicine that brings together resources and services for research communities to translate scientific discoveries into benefits for patients.

From the very start of the pandemic the EATRIS community, composed of university medical centres and research facilities, rapidly placed themselves and their expertise at the forefront of the COVID-19 fight.

EATRIS COVID-19 Research Forum



To accelerate efforts towards COVID-19 research, EATRIS developed a digital Research Forum. The platform allows EATRIS researchers to interact, discuss protocols, share resources and tools to collaborate on COVID-19 scientific priorities and funding proposals. [Find out more here.](#)

New COVID-19 test draws global attention



[Click to watch https://youtu.be/oOn3sQP92lg](https://youtu.be/oOn3sQP92lg)

Scientists from the head of the EATRIS Czech Republic node – the Institute of Molecular and Translational Medicine at Palacky University in Olomouc - have developed a self-test that involves gargling tap water. This is a pleasant alternative to the current method of nose-swab testing.

The pan-European television news network Euronews interviewed Professor Marian Hajduch, National Director of EATRIS-Czech Republic and director of the University's Institute of Molecular and Translational Medicine, who said the following: *"The test tube contains a powder which helps to stabilise the virus for several days at normal room temperature. This is the main difference from other COVID-19 tests, where the samples have to be transported and kept at cold temperatures."*


Finnish success story covered in Science Business



Professor Seppo Ylä-Herttuala – National Director of EATRIS-Finland – is part of a team of researchers from the University of Eastern Finland and the University of Helsinki who are working to develop a nasal spray vaccine against COVID-19. Newly-founded academic spin-out *Rokote Laboratories Finland Ltd* has used gene transfer technology developed by Professor Ylä-

Herttuala’s research group, and the technology has already been successfully used in several clinical trials to treat cardiovascular diseases and cancer. [Read more about the vaccine here.](#)

EATRIS offers regulatory support to COVID-19 vaccine researchers



[Click to watch https://youtu.be/NdT15KxRnmw](https://youtu.be/NdT15KxRnmw)

The EU-funded project, [TRANSVAC-2](#), of which EATRIS is a partner, accelerates vaccine research, by offering services to vaccine developers from academia and industry. EATRIS supported Researchers developing vaccine candidates against COVID-19 with regulatory compliance, ensuring that they are meeting the European Medicines Agency’s requirements for clinical trial authorisation.

EU-AMRI: BBMRI, EATRIS AND ECRIN JOIN FORCES


The mission of EATRIS is highly complementary with those of the European Clinical Research Infrastructure network ([ECRIN](#)) and the European research infrastructure for biobanking ([BBMRI](#)). The COVID-19 Fast Response Service is a coordinated and accelerated procedure for researchers to access the academic facilities, services and resources of the three medical research infrastructures, working together under the umbrella of the Alliance of Medical Research Infrastructures (EU-AMRI).



eatris

ECRIN
EUROPEAN CLINICAL RESEARCH
INFRASTRUCTURE NETWORK

BBMRI
Biobanking and
Biomolecular
Resources Research
Infrastructure



EU-AMRI driving change in policy

15 May 2020: hosted by the Croatian Presidency of the European Council, Toni Andreu (EATRIS Scientific Director) was a panelist on behalf of EATRIS, BBMRI and ECRIN




21 October 2020: OECD Global Science Forum - Mobilising science in response to COVID-19. Jacques Demotes (ECRIN General Director) was a panelist on behalf of EATRIS, BBMRI and ECRIN



24 March 2021: At the European Strategy Forum on Research Infrastructures Conference Open Session, Anton Ussi (EATRIS Operations and Finance Director) talks about the joint response to the COVID-19 pandemic



Publication in Clinical Infectious Diseases



EATRIS co-authored a paper in the Clinical Infectious Diseases journal together with BBMRI and ECRIN about the common strategic objectives and action lines of the European Alliance of Medical Research Infrastructures (AMRI), established to improve the research process and tackle

challenges related to diagnostic tests and biomarker development for Covid-19.

An effective response to the coronavirus disease 2019 (COVID-19) pandemic requires a better understanding of the biology of the infection and the identification of validated biomarker profiles that would increase the availability, accuracy, and speed of COVID-19 testing. In the publication, Emanuela Oldoni and colleagues describe the strategic objectives and action lines of the AMRI, established to improve the research process and tackle challenges related to diagnostic tests and biomarker development. Recommendations include: the creation of a European taskforce for validation of novel diagnostic products, the definition and promotion of criteria for COVID-19 samples biobanking, the identification and validation of biomarkers as clinical endpoints for clinical trials, and the definition of immune biomarker signatures at different stages of the disease. [Read more and access the full article here.](#)

5 practical steps to accelerate COVID-19 research published in EURACTIV



An article published in EURACTIV (an independent pan-European media network specialised in EU policies) outlined the role of European Medical Research Infrastructures as part of the global response. [Read more here.](#)

Fast Response Service

The COVID-19 Fast Response Service included:

- A list of complementary services/resources identified by each RI
- One single point of contact
- A response within 72 hours

[Find out more here.](#)

